G. S. Furga

Biography

    Dr. Giulio Superti-Furga, Ph.D., serves as Scientific Director and Chief Executive Officer of the Research Center of Molecular Medicine of the Austrian Academy of Sciences and Medical University of Vienna. Prof. Superti-Furga serves as Chief Executive Officer and Scientific Director at CeMM Forschungszentrum für Molekulare Medizin GmbH. He Co-founded Haplogen GmbH in 2010 and serves as its Member of Scientific Advisory Board. He has been an independent Team Leader at the EMBL and his research focussed on cytoplasmic tyrosine kinases and signal transduction since 1995. His most significant scientific contributions are the elucidation of basic regulatory mechanisms of tyrosine kinases in human cancers and the discovery of fundamental organization principles of the proteome of higher organisms. Prof. Superti-Furga served as an Adjunct professor at the University of Bologna in Italy and as an Editor for FEBS Letters. In 2000, he co-founded Cellzome Inc., a parent company of Cellzome AG, where he was a Scientific Director and responsible for the Heidelberg research site. Prof. Superti-Furga served as Scientific Director of Cellzome AG. He was a post-doctoral fellow and Team Leader at the European Molecular Biology Laboratory (EMBL) until 2004 and was its Staff Scientist since 1993. He consulted for major pharmaceutical companies working in this field. Prof. Superti-Furga serves as a Member of the Scientific Advisory Board of BIOCRATES Life Sciences AG and Cellzome AG. He is the author of more than 35 scientific publications and he is credited with discovering the importance of particular intramolecular interactions in the regulation of these enzymes. He did his undergraduate and graduate studies in molecular biology at the University of Zurich and at the Institute for Molecular Pathology in Vienna (I.M.P.). He completed his Ph.D. at the University of Zürich in 1990.

Research Interest

biomedicine